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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.02.002Abstract Approximately 20% of patients with colorectal cancer have metastatic disease at time of diagno-
sis, and another 25–35% develop metastases during the course of their disease. Liver, peritoneum, and
lungs are the most common sites of metastases. We report the case of a 60-year-old female who presented
with ocular metastasis 4 years after her initial curative-intent treatment for T3N1M0 rectal adenocarci-
noma. After local eye radiation therapy, she received palliative systemic chemotherapy and enjoyed a
good quality of life for 32 months before succumbing to progressive disease. Ocular metastasis of colorec-
tal cancer is rare. When present, it usually occurs in the setting of diffuse hematogenous spread. In addi-
tion to local therapy, systemic chemotherapy should also be considered.
KEYWORDS: Colorectal cancer; Ocular metastasisINTRODUCTIONColorectal cancer is the third most commoncause of cancer death in the United States.1Approximately 20% of patients with colorectal
cancer have distant metastases at diagnosis, and
another 30% develop metastases during their disease
course.2–4 The most common sites of metastases for
colorectal cancer include liver (77%), peritoneum
(25%), and lungs (22%).5
Primary intraocular neoplasia is relatively uncom-
mon; uveal melanoma is the most common primary
ocular malignancy among adults, with an annual inci-
dence rate of about six per million.6 However,
intraocular metastases occur more frequently with pri-
mary breast or lung cancers.7,8 Histology, other than
adenocarcinoma, is rare. The choroid is the most
common ocular site of metastases, accounting for
more than 80% of cases. In this case report, we pre-
sent a patient with choroidal metastasis from KRAS
wild-type rectal cancer which occurred 4 years after
her primary diagnosis.CASE REPORT
A 60-year-old African-American female with no prior
ocular history presented for ophthalmologic examina-
tion in July 2010, following 2 weeks of visual distur-
bance in the left eye. She initially described a ‘small
ﬂickering light’ in the periphery of the left temporal
visual ﬁeld. This was followed by worsening visual
acuity and the development of a ﬂoating ‘black’
scotoma in the temporal half of the left visual ﬁeld.
Ocular examination noted a visual acuity of
20/40 in the right eye and 20/400 in the left.
Fundoscopic examination of the left eye revealed a
15 mm · 15 mm creamy yellow amelanotic choroid
mass extending supranasally form the optic disk into
the superior nasal periphery. The lesion had a nodular
appearance at its edges and had 180 contact with the
optic nerve. It involved the macular region as well.
Overlying subretinal ﬂuid was noted centrally and
inferiorly, suggesting exudative retinal detachment
(Figure 1). Examination of the right eye revealed no
choroidal lesions. B-scan ultrasound demonstrated aarter 2015
Figure 1. Amelanotic nodular choroid mass (A, encircled red) extending supranasally form the optic disc (B, pointed blue) and involving macula (C,
encircled green).
OCULAR METASTASIS OF COLORECTAL CANCER case reportsolid mass with intermediate to high reﬂectivity and a
height of 3.6 mm (Figure 2A). There was no
extraocular extension. These ﬁndings were thought
to be consistent with choroidal metastasis.
This patient had a history of rectal adenocarci-
noma (T3N1M0), diagnosed in June 2006. She was
treated with neoadjuvant capecitabine-based
chemoradiation (5040 cGy over 5 weeks) followed
by a laparoscopic abdominoperineal resection (APR)
in September 2006, and three cycles of adjuvant cape-
citabine completed by December 2006. The surgical
specimen revealed a well-differentiated adenocarci-
noma extending to muscularis propria, and two of
11 lymph nodes were involved. The patient was lost
to follow-up, but had no medical complaints until
the current presentation.
After diagnosis of left eye choroidal metastasis, the
patient underwent further staging work-up with posi-
tron emission and computed tomography (PET/CT)
scan. This demonstrated multiple hypermetabolic
nodules in the lungs, right adrenal gland, lumbar spine
(L1), right sacrum and right inferior pubic ramus.
Magnetic resonance imaging (MRI) of the brain was
unremarkable. A ﬁne needle aspiration (FNA)
obtained from a lung nodule demonstratedHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015adenocarcinoma cells positive for cytokeratin-20,
CDX-2, and negative for cytokeratin-7 by immuno-
histochemistry, consistent with metastasis from a pri-
mary colorectal cancer. The KRAS gene exon 2 status
was wild-type. Overall, the patient was feeling well
without shortness of breath, cough or other systemic
complaints, and the Eastern Cooperative Oncology
Group (ECOG) performance status was 0.
With the goal of visual restoration, the patient was
treated with radiation therapy to the posterior half of
the left eye (3500 cGy over 14 fractions) in November
2010. Repeat ophthalmological and ultrasound exam-
ination demonstrated a partial regression. However,
there was no improvement in her vision.
Following completion of radiotherapy to ocular
metastasis, the patient began systemic chemotherapy
in December 2010 with intravenous 5-ﬂuorouracil
(5-FU), leucovorin, oxaliplatin (FOLFOX) and beva-
cizumab (Avastin) in two-weekly cycles. CT scans
after four cycles of chemotherapy demonstrated a par-
tial response. Ophthalmologic examination at that
time revealed a completely ﬂat residual lesion
(Figure 2B) with pigmentary changes. Of note, the
patient reported slight improvement in her vision
during the course of her chemotherapy. After 12177
Figure 2. Ultrasound examination of left eye. (A) At initial presentation, a 3.6 mm solid mass with intermediate to high reflectivity was noted (red
arrows), without any extraocular extension. (B) After completion of radiation and chemotherapy, complete flattening of lesion was noted (red
arrows).
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case report OCULAR METASTASIS OF COLORECTAL CANCERbi-weekly treatments (6 months), she developed a
grade 3 infusion allergic reaction to oxaliplatin, and
was continued on maintenance 5-FU and bevacizu-
mab treatments. After 8 months of chemotherapy,
the patient was noted to have disease progression
upon restaging CT scans in August 2011. However,
she did not report any deterioration in vision.
The patient decided to be treated with second-
line systemic chemotherapy on a clinical trial
(ECOG7208) with irinotecan, cetuximab and ramu-
cirumab, a monoclonal antibody against vascular
endothelial growth factor receptor-2 (VEGFR2), in
two-weekly cycles. The patient had disease response
on second-line therapy but required dose modiﬁca-
tions due to irinotecan-induced myelosuppression
(neutropenia); irinotecan was eventually discontinued
during cycle 24. Following cycle 28, cetuximab and
ramucirumab were also dose-reduced for skin toxicity
(rash). The patient continued on treatment with
cetuximab and ramucirumab until cycle 34 (January
2013), when she developed disease progression with
increasing bone (spine), and new brain metastases.
However, there was no evidence of progression of
the ocular metastasis. Palliative radiation to T12–L2
vertebral bodies and whole brain radiation were admi-
nistered. However, she continued to develop further
symptomatic spine, bone and leptomeningeal metas-
tases. The patient underwent palliative surgery with
internal ﬁxation of a right intertrochanteric femoral
fracture. Her performance status continued to decline,
with alterations of mental status. After detailed dis-
cussion with family, hospice care was initiated and
patient died in February 2013.DISCUSSION
The current case illustrates a rare site of metastasis for
colorectal cancer (CRC). It is now established that
metastasis is the most common cause of ocular malig-
nancy. Gastrointestinal tract cancers account for only
about 4% of ocular metastasis.7,9 Few series have
speciﬁcally described characteristics of ocular metasta-
sis of CRC. Utilizing OVID and MEDLINE, we
conducted a literature search to identify previously
reported cases of CRC with ocular metastasis that
describe the clinical characteristics of this uncommon
group. Keywords used for the literature search
included ‘colorectal neoplasms’, ‘metastasis’ and ‘eye
neoplasms’. Eight previously published cases were
retrieved (including one patient each with orbit and
anterior eye chamber metastases).10–17 The case of a
patient with rectal cancer metastatic to the anterior
chamber of the eye (between cornea and the iris)
was published as part of a case series, but details of
the individual patient were not available.17
Nevertheless, the authors emphasize the poor prog-
nosis among the 26 patients with various malignancies
metastatic to the anterior segment of the eye
(5.4 months), compared to those with orbit metas-
tases (15.6 months). Characteristics and outcomes of
the remaining seven patients and the patient pre-
sented in the current report are summarized in
Table 1.
‘Visual disturbance’ was the presenting symptom
among all CRC patients with intraocular metastasis.
In only one patient, the primary malignancy (CRC)
was diagnosed after the onset of visual disturbanceHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015
Table 1. Summary of literature review of colorectal cancer with ocular metastasis.
Age (yr) Sex Time from initial Dx Initial site Other mets Ocular extent O-Surg O-RT Chemo Outcome
Khawaja et al. 60 F 4 yr Rectum Yes Choroid No Yes FOLFOX-B Died at 32 mo
Apte et al. 39 M 3 mo Cecum Yes Retina Excision Yes FOLFIRI Alive at 7 mo
Howard et al. 63 M 3 yr Ascending colon Yes Retina, choroid, orbit Enucl No No Died at 16 mo
Kennedy et al. 51 M – Rectosigmoid No Choroid, macula Enucl No No Died at 9 mo
Lin et al. 43 M 8 yr Sigmoid Yes Choroid No No i-B Died at 4 mo
Kuo et al. 65 F 20 mo Colon Yes Choroid No No i-B Alive at 5 mo
Ward et al. 52 F NA Colon Yes Choroid b/l No No No Diet at 1 mo
Hisham et al. 32 F 10 mo Rectum Yes Orbit No Yes No Died at 2 mo
M: male; F: female; Yr: years; Mo: months; Dx: Diagnosis; NA: not available; Mets: metastasis; b/l: bilateral; O-Surg: ocular surgery; Enucl: enucleation; O-RT: ocular radiation therapy; B:
bevacizumab; i-B: intravitreous bevacizumab.
OCULAR METASTASIS OF COLORECTAL CANCER case reportand no other sites of metastases were found.12 All of
the other patients had a known history of colorectal
cancer and had developed systemic metastases by
the time visual disturbance developed. Two patients
with treated only with eye enucleation and no other
treatment, and died with systemic progression within
9 and 16 months, respectively.11,12 Two patients were
treated with intravitreous bevacizumab only.13,14 One
of these patients, with bilateral choroid metastasis,
had signiﬁcant response in one eye while the tumor
continued to progress in the other eye, presumably
due to massive exudation hindering bevacizumab from
reaching the metastatic tumor. This patient died
4 months after his ocular presentation.13 The other
patient treated with intravitreous bevacizumab also
received radiation therapy for brain metastasis, and
was alive after 5 months of follow-up.14 One patient
underwent excision of the retinal mass followed by
palliative ocular radiation and systemic chemotherapy
with 5-FU, leucovorin and irinotecan (FOLFIRI),
and was alive after 7 months of follow-up.10 One
patient was offered palliative ocular radiotherapy but
declined any treatment, and died after 1 month.15
Another patient received palliative radiotherapy but
died of intestinal obstruction 2 months later.16
The patient reported here was initially treated with
local radiation therapy for ocular metastasis followed
by systemic chemotherapy, and enjoyed a good quality
of life for 32 months before succumbing to progres-
sive disease, with bone, brain, and leptomeningeal
metastases. This report describes the longest follow-
up reported in a patient with ocular metastasis of col-Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015orectal cancer and therefore provides a unique oppor-
tunity to learn about the natural history of this rare
presentation.
Ocular metastases occur in the context of diffuse
hematogenous spread of CRC, and are most fre-
quently accompanied by other systemic metastases.
The addition of systemic chemotherapy to local treat-
ment should theoretically yield better outcomes, and
the current review of literature appears to support this
approach. One patient, described in the literature,
who did not have any other evidence of distant metas-
tases, received only local therapy (enucleation) and
died after 9 months, presumably from generalized dis-
ease progression. On the other hand, two patients
who received systemic chemotherapy had other
known metastases; both of these were alive at the
end of their respective follow-up period.
To our knowledge, the current case is the ﬁrst
report of systemic bevacizumab use in the setting of
ocular metastasis of CRC. Use of intravitreous beva-
cizumab is common for a variety of ocular conditions,
including exudative age-related macular degeneration,
diabetic retinopathy, ocular veno-occlusive disease and
primary or metastatic ocular malignancies.18 As dis-
cussed above, the two patients who received
intravitreous bevacizumab for CRC with ocular
metastasis had mixed results.
In conclusion, ocular metastasis of CRC is rare
and occurs as part of generalized metastasis to multi-
ple organ sites. The addition of systemic chemother-
apy to local treatment of ocular disease may improve
overall outcomes.179
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